JPRN-UMIN000032901
Recruiting
Phase 4
The investigation of safety and efficacy of short hydration GC therapy in metastatic urothelial carcinoma patients - The investigation of safety and efficacy of short hydration GC therapy
agoya City University Graduate School of Medical Sciences0 sites10 target enrollmentJune 20, 2018
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- advanced or metastatic urothelial carcinoma patients
- Sponsor
- agoya City University Graduate School of Medical Sciences
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. patients who had allergy in gemcitabine 2\. patients who had allergy in cisplatin 3\. previously treated patients by gemcitabine, or cisplatin 4\. patients who had sign of interstitial pneumoniae or pulmonary fibrosis 5\. patients previously treated in chest by radiation therapy 6\. patients who have infection or fever 7\. pregnant patients 8\. patients giving lactation 9\. patients including severe diseases 10\. unadequate patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary SyndromesHeart AttackHeart Disease10082206NL-OMON34504Anthera Pharmaceuticals, Inc576
Active, not recruiting
Not Applicable
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes - VISTA-16Treatment of patients with Acute Coronary Syndromes (ACS)MedDRA version: 12.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-016812-18-CZAnthera Pharmaceuticals, Inc.6,504
Active, not recruiting
Not Applicable
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes - VISTA-16Treatment of patients with Acute Coronary Syndromes (ACS)MedDRA version: 12.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-016812-18-DEAnthera Pharmaceuticals, Inc.6,504
Active, not recruiting
Not Applicable
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes (VISTA-16) - VISTA-16Acute Coronary SyndromesMedDRA version: 9.1Level: LLTClassification code 10051592EUCTR2009-016812-18-ITANTHERA PHARMACEUTICALS6,504
Active, not recruiting
Not Applicable
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes - VISTA-16Treatment of patients with Acute Coronary Syndromes (ACS)MedDRA version: 12.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-016812-18-HUAnthera Pharmaceuticals, Inc.6,504